Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years and Over|
Inclusion Criteria:Age. 1. Male or female patients age ≥ 18 years of age at the time of first dose. Type of Participant and Disease Characteristics. 2. Histologically or cytologically confirmed metastatic UM or unresectable UM patients. 3. HLA-A*02:01 positive. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Informed Consent. 5. Ability to provide and understand informed consent prior to procedures [if required] Contraception. 6. Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 1 week after the final dose of the program intervention; cessation of birth control after this point shall be discussed with a responsible physician. 1. Pregnant or lactating women are prohibited from enrolling on this program. 2. Male participants are not allowed to donate sperm from the time of enrolment until 3 months post- administration of program interventions.
Exclusion Criteria:Disease Under Study and Prior Anticancer Therapy. 1. Presence of untreated or symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or cord compression. NOTE: Participants with treated CNS lesions may enroll provided all of the following apply: 1. Treated CNS lesions must be radiographically stable for ≥ 2 weeks after intervention (surgery and/or radiation). 2. Participants must be neurologically stable off systemic corticosteroids for at least 2 weeks prior to first planned administration of tebentafusp. 2. Receipt of anticancer therapy for the disease under study within the following times prior to the first planned dose of program intervention: 1. Cellular therapies (e.g., T-cell therapies): 90 days. 2. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)- targeted immunotherapies (e.g., ipilimumab): 28 days. 3. All other immunotherapies, including PD-(L)1-targeted immunotherapies (e.g., atezolizumab, pembrolizumab): 21 days. 4. All other systemic therapies: 14 days. 5. Radiotherapy: 14 days (excepting palliative radiotherapy to a limited field [e.g., for a focally painful tumor mass], which may be administered within 14 days provided there are no ongoing related Grade 2 or higher toxicities) Medical Conditions and Concomitant Medications. 3. Systemic treatment with steroids or any other immunosuppressive drug use within 2 weeks of the planned first dose of program intervention, with the following exceptions: 1. Treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ≤ 12 mg daily or the equivalent. 2. Local steroid therapies (e.g., optic, ophthalmic, intra- articular, or inhaled medications) are acceptable. 3. Premedication for allergy to contrast reagent. 4. Steroids for management of CNS metastases > 2 weeks prior to the planned first dose of program intervention. 4. Any relevant medical condition, which in the opinion of the treating physician, would prevent the participant enrolling into the Program due to concerns related to safety, compliance with procedures, or interpretation of program results. 5. Chronic viral infections as indicated below. NOTE: Testing for hepatitis C virus (HCV) status prior to enrollment is not necessary unless clinically indicated. 1. Known history of human immunodeficiency virus (HIV) infection. 2. Known HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to the planned first dose of program intervention and viral load confirmed as undetectable during Screening. 3. Known HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable during Screening. Diagnostic Assessments. 6. Participant with an out-of-range Screening laboratory values defined as shown below. NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood product transfusion and ≥ 14 days from any dose of hematologic growth factor. 1. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 30 mL/minute. 2. Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN. 3. Alanine aminotransferase > 5 × ULN. 4. Aspartate aminotransferase > 5 × ULN. 5. Platelet count < 50 × 109/L. 6. Hemoglobin < 8 g/dL. 7. Clinically significant cardiac disease or impaired cardiac function, including any of the following: 1. Congestive heart failure (New York Heart Association Class ≥ 3) 2. Uncontrolled hypertension defined as systolic blood pressure [BP] > 160 mmHg or diastolic BP > 110 mmHg with the following requirements: 1. If initial measurement is elevated, additional assessments should be taken where each assessment is the mean value of 3 measurements taken at least 5 minutes apart. 2. Eligibility is based on the average of at least 2 assessments taken at least 1 hour apart. 3. Acute myocardial infarction or unstable angina pectoris < 6 months prior to the planned first dose of program intervention
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Principal Investigator Affiliation||N/A|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:
For additional contact information, you can also visit the trial on clinicaltrials.gov.